PTAB Nixes 'Recycled' Bid For AIA Review Of Suboxone Patent
The Patent Trial and Appeal Board has rejected BioDelivery Sciences International's petition for review of Reckitt Benckiser Pharmaceuticals Inc.'s patent on the opiate addiction treatment Suboxone, ruling that the petition "recycled"...To view the full article, register now.
Already a subscriber? Click here to view full article